A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-25 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
==== Spanish colonial America ==== In Jamaica and elsewhere in the Caribbean area, the Spanish enslaved many of the Taino natives. Some of them escaped, and some hurled themselves and their children off of cliffs to avoid enslavement, but most died from European diseases and overwork. The practice began under Christopher Columbus, who was looking for gold to finance his future expeditions, and was continued by the other conquistadors who followed in his wake. In 1519, Hernán Cortés brought the first modern slave to Mexico. In the mid-16th century, the Spanish New Laws, prohibited slavery of the indigenous people, including the Aztecs. A labour shortage resulted. This led to the African slaves being imported, as they were not susceptible to smallpox. In exchange, many Africans were afforded the opportunity to buy their freedom, while eventually others were granted their freedom by their masters. Spain practically did not trade in slaves until 1810 after the rebellions and independence of its American territories or viceroyalties. After the Napoleonic invasions, Spain had lost its industry and its American territories, except in Cuba and Puerto Rico, where the African slave trade to Cuba began on a massive scale from 1810 onwards. It was started by French planters exiled from the French lost colony Saint Domingue (Haiti) who settled in the eastern part of Cuba. In 1789, the Spanish Crown led an effort to reform slavery, as the demand for slave labour in Cuba was growing.
=== Resistive electrolytic hygrometers === Resistive electrolytic hygrometers use a sensing element in the form of a liquid electrolyte held in between of two small glass rods by capillary force. The electrolyte changes resistance if it absorbs or loses water vapor. The resistance is directly proportional to relative air humidity and therefore also to water activity of the sample (once vapor–liquid equilibrium is established). This relation can be checked by either verification or calibration using saturated salt-water mixtures, which provide a well-defined and reproducible air humidity in the measurement chamber. The sensor does not have any physically given hysteresis as it is known from capacitance hygrometers and sensors, and does not require regular cleaning as its surface is not the effectively sensing element. Volatiles, in principle, influence the measurement performance—especially those that dissociate in the electrolyte and thereby change its resistance. Such influences can easily be avoided by using chemical protection filters that absorb the volatile compound before arriving at the sensor.
Jessie McTavish, a nurse convicted and then controversially cleared of the 1974 murder of an 80-year-old patient with insulin, has been identified as the likely inspiration for Norris. She had worked at Ruchill Hospital in Glasgow, less than a mile from where Norris grew up. She had been released on appeal after her defence team successfully argued that the trial judge had inadvertently misled the jury in his final summing up, even though the appeal court judges said that it was something a "few words could have cured" and that there was enough evidence to support the prosecution. Norris's personal tutor at university gave a specific talk to him and other students on her case on 11 January 2001, a year before Norris committed his first attack, in which Norris used the same method as McTavish had been accused of using. Norris was tasked with "reviewing" her conduct, and in doing so, he would have learned that insulin is the perfect weapon for murder because it leaves the blood very quickly. Just like Norris, McTavish had 'predicted' the exact time when a healthy patient would die. She was able to continue her career in nursing after she was released on appeal. Norris had notably also attended lectures in 1999 on diabetes and the treatment of diabetic patients with insulin, where he learned about the consequences of blood sugars being too high or too low.
== High sensitivity variants of the biuret test == Two major modifications of the biuret test are commonly applied in modern colorimetric analysis of peptides: the bicinchoninic acid (BCA) assay and the Lowry assay. In these tests, the Cu+ formed during the biuret reaction reacts further with other reagents, leading to a deeper color. In the BCA test, Cu+ forms a deep purple complex with bicinchoninic acid (BCA), which absorbs around 562 nm, producing the signature mauve color. The water-soluble BCA/copper complex absorbs much more strongly than the peptide/copper complex, increasing the sensitivity of the biuret test by a factor of around 100: the BCA assay allows to detect proteins in the range of 0.0005 to 2 mg/mL. Additionally, the BCA protein assay gives the important benefit of compatibility with substances such as up to 5% surfactants in protein samples. In the Lowry protein assay, Cu+ is oxidized back to Cu2+ by MoVI in the Folin–Ciocalteu reagent, which forms molybdenum blue (MoIV). Tyrosine residues in the protein also form molybdenum blue under these circumstances. In this way, proteins can be detected in concentrations between 0.005 and 2 mg/mL. Molybdenum blue can in turn bind certain organic dyes such as malachite green and Auramine O, resulting in further amplification of the signal.
Silicosis is an occupational lung disease caused by the inhalation of respirable crystalline silica dust. It is characterized by lung inflammation and fibrosis that most commonly affects the upper lobes and is classified as a form of pneumoconiosis. The disease occurs in chronic (simple and progressive massive fibrosis), accelerated, or acute forms, depending on the intensity and duration of exposure. Common symptoms include shortness of breath, cough, fatigue, and cyanosis in severe cases. Because its clinical and radiographic features can resemble those of tuberculosis, pneumonia, or pulmonary edema, silicosis is sometimes misdiagnosed. There is no curative treatment; management focuses on symptom control and the prevention of complications. Silicosis is largely preventable through effective workplace controls that limit airborne silica exposure, such as engineering controls, ventilation, and appropriate respiratory protection.
Sources: en.wikipedia.org
== Security cooperation == The agreement aligns with simultaneous U.S.–Pakistan counterterrorism collaboration: the U.S. designated the Balochistan Liberation Army (BLA) as a terrorist organization, a move lauded by Karachi and carried out amid discussions surrounding the trade accord.
Scotland was traditionally divided into four whisky regions: Campbeltown, The Highlands, The Isle of Islay and The Lowlands. Due to the large number of distilleries found there, the Speyside area became the fifth, recognised by the Scotch Whisky Association (SWA) as a distinct region in 2014. The whisky-producing islands other than Islay are not recognised as a distinct region by the SWA, which groups them into the Highlands region.
==== Reception to Antonov's work ==== Upon Dishonored's release, Antonov stated that he felt his work on Dunwall surpassed his work on City 17: "for me, [...] Dunwall is far superior by quantity of design, quality of design, and precision". PC Gamer and Rock Paper Shotgun have since listed Dunwall as one of the best cities in gaming. In 2022, Levi Winslow wrote that it is the most "vivid and memorable" city they had ever explored in a game, "so environmentally and thematically intertwined that it gives me the creeps"; Dishonored makes significant usage of environmental storytelling, showing the effects of the plague on Dunwall by having most of its rooms be unoccupied, the presence of fresh food and burning fireplaces indicating they were abandoned by their occupants shortly prior to the events of the game. Much of the city is littered with corpses that the rats can be seen feasting on.
=== Hippurate === The Hippurate diagnostic test is used to differentiate between Gardnerella vaginalis, Campylobacter jejuni, Listeria monocytogenes and group B streptococci using the chemical Hippurate. The Hippurate hydrolysis pathway, capable by organisms with the necessary enzymes, produces glycine as a byproduct. Using the indicator ninhydrin, which changes color in the presence of glycine, will display either a colorless product, a negative result, of a dark blue color, a positive result.
Glutamatergic means "involving the release of, or activated by, glutamate". A glutamatergic agent (or drug) is a chemical that directly modulates the excitatory amino acid (glutamate/aspartate) system in the body or brain. Examples include:
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.